Document:

EX-10.2

 Exhibit 10.2 

March 12, 2015 
 By
Telefacsimile (81-3-3811-1459) 
 With Follow Up by E-mail 

Eisai Co., Ltd. 
 Attention: Chief Product Creation Officer 

Koishikawa 4-6-10 
 Bunkyo-Ku 

Tokyo 112-8088 
 Japan 

 

	 	Re:	Companion Diagnostics Agreement with Roche Molecular Systems, Inc. (“RMS”) 

 Dear Sir:

 Reference is hereby made to (a) the Amended and Restated Collaboration and License Agreement dated as of March 12, 2015 (the
“Amended and Restated Collaboration Agreement”), by and between Eisai Co., Ltd. (“Eisai”) and Epizyme, Inc. (“Epizyme”), (b) the Companion Diagnostics Agreement dated December 18, 2012, as amended by the First
Amendment thereto dated May 31, 2013 (the “RMS Agreement”), by and between Epizyme and Eisai, on the one side, and RMS, on the other side and (c) the prior letter agreement dated December 21, 2012 (the “Prior Letter
Agreement”), by and between Epizyme and Eisai, regarding the RMS Agreement. 
 The purpose of this letter is to amend and restate, in
their entirety, the agreements set forth in the Prior Letter Agreement regarding certain matters set forth in the RMS Agreement, including the activities of RMS, Eisai and Epizyme under the RMS Agreement more specifically described under Exhibit A
thereto (the “CDx Development Activities”). Accordingly, as to such matters arising from and after the date hereof, this letter supersedes in its entirety the Prior Letter Agreement. In particular, Eisai and Epizyme hereby agree that: 

1. Subject to paragraph 3 below, from and after the date hereof Epizyme shall be responsible for (a) all payments due to RMS under
Sections 3.2, 7.1, and 7.2 of the RMS Agreement, (b) all payments due to RMS under the last paragraph of Exhibit B of the RMS Agreement except those payments for which Epizyme is solely responsible pursuant to paragraph 2 below and those
payments for which Eisai is solely responsible pursuant to paragraph 2 below, (c) interest on late payments due to RMS under Section 7.3 of the RMS Agreement, and (d) all Termination Fees (as defined in the RMS Agreement) and other
amounts due to RMS under Section 15.7(a) and 15.7(b) of the RMS Agreement ((a) through (d), the “Base Payments”). 

 Eisai Co., Ltd. 

March 12, 2015 
  Page
 2
 
  

 2. Subject to paragraphs 8, 9, and 10 below, as between Eisai and Epizyme, (a) Epizyme
shall (i) (x) indemnify and defend the RMS Indemnitees (as defined in the RMS Agreement) in accordance with the RMS Agreement from and against all Liabilities (as defined in the RMS Agreement) from any Third Party Claims (as defined in the
RMS Agreement) incurred by any RMS Indemnitee and (y) be responsible for and pay any damages payable to RMS under or in connection with the RMS Agreement, in each case ((x) and (y)) arising from or occurring as a result of (A) the
negligence or willful misconduct of Epizyme or any of its Affiliates (as defined in the Amended and Restated Collaboration Agreement) or any of their respective directors, officers, or employees (each, an “Epizyme Party”) or (B) any
action or inaction of any Epizyme Party that results in a breach of the RMS Agreement by Pharmaceutical Partners, and (ii) be responsible for and pay any amount payable to RMS pursuant to the last paragraph of Exhibit B of the RMS Agreement
arising from or occurring as a result of any action or inaction of any Epizyme Party, and (b) Eisai shall (i) (x) indemnify and defend the RMS Indemnitees in accordance with the RMS Agreement from and against all Liabilities from any
Third Party Claims incurred by any RMS Indemnitee and (y) be responsible for and pay any damages payable to RMS under or in connection with the RMS Agreement incurred by any RMS Indemnitee, in each case ((x) and (y)) arising from or occurring
as a result of (A) the negligence or willful misconduct of Eisai or any of its Affiliates or any of their respective directors, officers, or employees (each, an “Eisai Party”) or (B) any action or inaction of any Eisai Party that
results in a breach of the RMS Agreement by Pharmaceutical Partners, and (ii) be responsible for and pay any amount payable to RMS pursuant to the last paragraph of Exhibit B of the RMS Agreement arising from or occurring as a result of any
action or inaction of any Eisai Party. 
 3. Subject to the relevant decision-making procedures, rights and powers set forth in the Amended
and Restated Collaboration Agreement, representatives of Epizyme shall participate in Project Teams and the JSC (each as defined in the RMS Agreement) as set forth in the RMS Agreement. Where the terms of the RMS Agreement require or permit
Pharmaceutical Partners (as defined in the RMS Agreement) to vote on or approve any matter, Eisai and Epizyme shall seek to perform such obligations or exercise such rights by consensus; provided, however, that if Eisai and Epizyme are not able to
agree on any such matter within a reasonable period of time, such matter shall be decided in accordance with the Amended and Restated Collaboration Agreement. In addition, neither Epizyme nor Eisai shall cause any election to be made under the RMS
Agreement that would obligate the other party to bear payment obligations under the RMS Agreement in addition to the payment obligations set forth in this letter agreement in the absence of the prior agreement of such other party. 

4. Eisai and Epizyme acknowledge and agree that nothing in the RMS Agreement shall amend or modify the relative rights or obligations of Eisai
and Epizyme under the Amended and Restated Collaboration Agreement, including Epizyme’s sole right to determine all Development activities with respect to the diagnostic product(s) developed and commercialized under the RMS Agreement
(“Roche Diagnostics”), subject to Article 4 of the Amended and Restated Collaboration Agreement and subject to EISAI’s right to make such determinations as to Japan-Specific Development Activities (as defined in the Amended and
Restated Collaboration Agreement), Epizyme’s sole right to 

 Eisai Co., Ltd. 

March 12, 2015 
  Page
 3
 
  

 
determine all Commercialization activities with respect to the Roche Diagnostics in the EPIZYME Territory (as defined in the Amended and Restated Collaboration Agreement) and Eisai’s sole
right to determine all Commercialization activities with respect to the Roche Diagnostics in the EISAI Territory (as defined in the Amended and Restated Collaboration Agreement), provided that (a) such rights of Eisai in the EISAI Territory
shall revert to Epizyme in any termination circumstance under the Amended and Restated Collaboration Agreement in which development and commercialization rights to E7438, which is a Licensed Compound (as defined in the Amended and Restated
Collaboration Agreement), or any other Therapeutic Product (as defined in the Amended and Restated Collaboration Agreement) to which the CDx Development Activities relate, as applicable, in the EISAI Territory revert to Epizyme in accordance with
Section 12.5.1 of the Amended and Restated Collaboration Agreement (such termination, an “Epizyme Reversion Termination”) and (b) such rights of Epizyme in the EPIZYME Territory shall revert to Eisai in any termination
circumstance under the Amended and Restated Collaboration Agreement in which development and commercialization rights to E7438 or any other Therapeutic Product to which the CDx Development Activities relate, as applicable, in the EPIZYME Territory
revert to Eisai in accordance with Section 12.5.2 of the Amended and Restated Collaboration Agreement (such termination, an “Eisai Reversion Termination”) . 

5. Notwithstanding anything in the Amended and Restated Collaboration Agreement to the contrary, Epizyme and Eisai each acknowledges and
agrees that in no event shall (a) any amounts invoiced by Roche, its Affiliates or any sublicensee for sales of the Roche Diagnostics constitute or be included in the calculation of Net Sales for any purpose of the Amended and Restated
Collaboration Agreement, (b) Eisai pay Epizyme or Epizyme pay Eisai any royalties or milestones with respect to sales of the Roche Diagnostics, or (c) any Roche Diagnostic constitute a Licensed Product for purposes of Section 6.3 of
the Amended and Restated Collaboration Agreement. 
 6. Epizyme shall be responsible for all amounts payable by Pharmaceutical Partners
pursuant to Section 5.12(a) of the RMS Agreement or any agreement entered into pursuant to Section 5.12(a) of the RMS Agreement (the “Roche Payments”). Eisai and Epizyme acknowledge and agree that all Roche Payments shall, for
all purposes of the Amended and Restated Collaboration Agreement (including Section 6.4.4), constitute amounts paid by Epizyme to a Third Party with respect to license rights to Third Party intellectual property licensed by Epizyme that Epizyme
reasonably believes are necessary for the Development or Commercialization of E7438 or any Related Therapeutic Product. 
 7. Any rights and
interests in Know-How and Patents (each as defined in the Amended and Restated Collaboration Agreement) that Pharmaceutical Partners obtain pursuant to the RMS Agreement (including Pharmaceutical Partners Information and Pharmaceutical Partners
Project Inventions, each as defined in the RMS Agreement) shall be deemed to be rights and interests in Joint Know-How and Joint Patent(s), respectively, under the Amended and Restated Collaboration Agreement. 

 Eisai Co., Ltd. 

March 12, 2015 
  Page
 4
 
  

 8. Upon any Epizyme Reversion Termination, Epizyme shall assume and be solely responsible
for, and shall pay, perform and discharge, all payment obligations and other obligations of Pharmaceutical Partners under and pursuant to the RMS Agreement accruing from and after the effective date of such Epizyme Reversion Termination (including
any Termination Fees), and Epizyme shall, in accordance with Section 11.3 of the Amended and Restated Collaboration Agreement, indemnify, defend and hold harmless Eisai and its Affiliates, and its and their respective directors, officers,
employees and agents, from and against any and all Losses (as defined in the Amended and Restated Collaboration Agreement) arising out of or resulting from the RMS Agreement or Epizyme’s breach of its obligations under this paragraph 8
following such Epizyme Reversion Termination. 
 9. Not later than the date on which Eisai elects to effect an Eisai Reversion Termination
in accordance with Section 12.5.2(b) of the Amended and Restated Collaboration Agreement, Eisai shall notify Epizyme in writing that either (i) Eisai desires to keep the RMS Agreement in force, in which case Eisai shall assume and be
solely responsible for, and shall pay, perform and discharge, all payment obligations and other obligations of Pharmaceutical Partners under and pursuant to the RMS Agreement accruing from and after the effective date of such Eisai Reversion
Termination (including any Termination Fees), and Eisai shall, in accordance with Section 11.3 of the Amended and Restated Collaboration Agreement, indemnify, defend and hold harmless Epizyme and its Affiliates, and its and their respective
directors, officers, employees and agents, from and against any and all Losses (as defined in the Amended and Restated Collaboration Agreement) arising out of or resulting from the RMS Agreement or Eisai’s breach of its obligations under this
clause (i) following such Eisai Reversion Termination or (ii) Eisai desires not to keep the RMS Agreement in force, in which case, subject to paragraph 10, (A) Epizyme and Eisai shall immediately thereafter terminate the RMS Agreement
and cooperate to wind down the RMS Agreement, (B) Epizyme shall remain responsible for Base Payments and Roche Payments accruing from and after the effective date of such Eisai Reversion Termination, and (C) Epizyme and Eisai shall remain
responsible for indemnification obligations and damages with respect to the RMS Agreement as provided in paragraph 2. Any failure by Eisai to provide notification under clause (i) or (ii) of the immediately preceding sentence by the date
on which Eisai elects to effect an Eisai Reversion Termination in accordance with Section 12.5.2(b) of the Amended and Restated Collaboration Agreement shall constitute notification by Eisai under clause (ii) of the immediately preceding
sentence. 
 10. In the event that (a) Eisai provides notification in accordance with clause (ii) of paragraph 9 and
(b) within three hundred sixty-five (365) days after the effective date of termination of the RMS Agreement, Eisai or any of its Affiliates enters into an agreement with RMS or any of its Affiliates with respect to the research,
development or commercialization of any diagnostic product related to EZH2 (as defined in the Amended and Restated Collaboration Agreement), then Eisai shall (i) notify Epizyme of its entry into such agreement within ten (10) days after
such entry, (ii) reimburse Epizyme for all Termination Fees and all other Base Payments and Roche Payments accruing from and after the effective date of such Eisai Reversion Termination paid by Epizyme pursuant to clause (ii) of paragraph
9 not later than thirty (30) days after delivery by Epizyme of an invoice therefor, and (iii)

 Eisai Co., Ltd. 

March 12, 2015 
  Page
 5
 
  

 
assume and be solely responsible for, and shall pay, perform and discharge, all payment obligations and other obligations of Pharmaceutical Partners under and pursuant to the RMS Agreement
accruing from and after the effective date of such Eisai Reversion Termination (to the extent not then paid by Epizyme pursuant to clause (ii) of paragraph 9), and Eisai shall, in accordance with Section 11.3 of the Amended and Restated
Collaboration Agreement, indemnify, defend and hold harmless Epizyme and its Affiliates, and its and their respective directors, officers, employees and agents, from and against any and all Losses arising out of or resulting from the RMS Agreement
or Eisai’s breach of its obligations under this clause (iii) following such Eisai Reversion Termination. 
 11. Except as
expressly amended hereby, all terms of the Amended and Restated Collaboration Agreement shall remain in full force and effect. This letter agreement and any dispute arising from the performance or breach hereof shall be governed by and construed and
enforced in accordance with the laws of the State of New York excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this letter to the substantive law of another jurisdiction. This
letter agreement may be signed in counterparts, each and every one of which shall be deemed an original, notwithstanding variations in format or file designation which may result from the electronic transmission, storage and printing of copies from
separate computers or printers. Facsimile signatures and signatures transmitted via PDF shall be treated as original signatures. 
 [REMAINDER OF THIS PAGE
INTENTIONALLY LEFT BLANK] 

 Eisai Co., Ltd. 

March 12, 2015 
  Page
 6
 
  

 Please countersign this letter below to signify Eisai’s agreement to the terms set forth above,
whereupon this letter agreement will become a binding agreement between Eisai and Epizyme. 
  

			
	Very truly yours,
	
	EPIZYME, INC.
		
	By:		 /s/ Robert Gould

	Name:		Robert Gould
	Title:		President and CEO

 Acknowledged and agreed: 

EISAI CO., LTD. 
  

			
	By:		 /s/ Hideki Hayashi

	Name:		Hideki Hayashi
	Title:		Representative Corporate Officer

 Corporate Planning & Strategy and Chief Information Officer 

 

	Cc:	Eisai Co., Ltd., Attention: General Counsel (Telefacsimile 81-3-3811-5535) 

	 	Eisai Inc., Attention President and General Counsel (Telefacsimile 201-746-3201)EX-4.2

 Exhibit 4.2 

EXECUTION VERSION 
 BARCLAYS PLC

 Officer’s Certificate 

In connection with the issuance of $1,000,000,000 aggregate principal amount of 2.00% Fixed Rate Senior Notes due 2018 (the “2018
Notes”) and $2,000,000,000 aggregate principal amount of 3.65% Fixed Rate Senior Notes due 2025 (the “2025 Notes” and, together with the 2018 Notes, the “Securities”) of Barclays PLC (the “Company”), I, Tim Allen,
hereby certify pursuant to Sections 1.02, 3.01 and 3.03 of the Senior Debt Securities Indenture (the “Indenture”), dated as of November 10, 2014, between the Company and The Bank of New York Mellon acting through its London Branch, as
Trustee (the “Trustee”), in connection with the request contained in the accompanying Authentication Order of an even date herewith (the “Authentication Order”) that the Trustee authenticate and deliver the Securities as therein
provided, as follows: 
 1. I have read the conditions and any applicable covenants provided for in the Indenture relating to the issuance
and authentication and delivery of the Securities, including Sections 1.02, 2.01, 3.01 and 3.03 thereof, and in respect of compliance with which this certificate is being delivered, and the definitions in the Indenture relating thereto; 

2. The statements contained in this Certificate are based on my review of the Authentication Order and (i) the minutes of a meeting of
the board of directors of the Company (the “Board”) held on December 12, 2013, (ii) the minutes of a meeting of the Board held on December 12, 2013, as amended by resolutions of the Board adopted at a meeting held on
June 19, 2014, (iii) the approval of the Group Finance Director and the written resolutions of the Treasury Committee of the Company (the “Treasury Committee”) passed on May 1, 2014 and June 13, 2014, (iv) the
minutes of a meeting of the Board held on December 11, 2014 and (v) the written resolution of the Treasury Committee passed on March 11, 2015 and pursuant to such resolutions, minutes and approval, I hereby confirm that the form and
terms of the 2018 Notes (as set forth in Annex A-1 and Annex A-3) and the form and terms of the 2025 Notes (as set forth in Annex A-2 and Annex A-3) were established in conformity with the provisions of the Indenture;

 3. In my opinion, I have made such examination and investigation as is necessary to enable me to express an informed opinion as to
whether or not such conditions and any applicable covenants have been complied with; and 
 4. I am of the opinion that such conditions and
any applicable covenants, and all conditions precedent provided for in the Indenture relating to the request contained in the Authentication Order that the Trustee authenticate and deliver the Securities as therein provided, have been complied with
and the form and terms of the Securities have been established in conformity with the provisions of the Indenture. 

							
	Dated: March 16, 2015						
				
							 /s/ Tim Allen

					Name:		Tim Allen
					Title:		Director, Capital Markets Execution

  
 Signature Page to
Officer’s Certificate pursuant to 1.02, 3.01 and 3.03 of the Indenture 

 Annex A-1 

Form and Terms of the 2018 Notes 
  

			
	Title of 2018 Notes:		2.00% Fixed Rate Senior Notes due 2018
		
	Issue Price:		99.991%
		
	Aggregate Principal Amount of 2018 Notes:		$1,000,000,000
		
	Maturity Date:		March 16, 2018
		
	Interest Rate:		2.00% per annum, accruing from March 16, 2015
		
	Form of 2018 Notes:		The 2018 Notes will be issued in the form of global notes that will be deposited with The Depository Trust Company on the closing date. Each global note will be registered in the name of Cede & Co. and executed and delivered in
substantially the form attached hereto as Exhibit A.

 Annex A-2 

Form and Terms of the 2025 Notes 
  

			
	Title of 2025 Notes:		3.65% Fixed Rate Senior Notes due 2025
		
	Issue Price:		99.685%
		
	Aggregate Principal Amount of 2025 Notes:		$2,000,000,000
		
	Maturity Date:		March 16, 2025
		
	Interest Rate:		3.65% per annum, accruing from March 16, 2015
		
	Form of 2025 Notes:		The 2025 Notes will be issued in the form of global notes that will be deposited with The Depository Trust Company (“DTC”) on the closing date. Each global note will be registered in the name of Cede & Co. and executed
and delivered in substantially the form attached hereto as Exhibit B.

 Annex A-3 

Terms applying to both the 2018 Notes and the 2025 Notes 
  

			
	Issue Date of Securities:		March 16, 2015
		
	Denomination:		$200,000 and integral multiples of $1,000 in excess thereof
		
	Depositary		The Depository Trust Company
		
	Initial Holder		Cede & Co.
		
	Interest Payment Dates:		 March 16 and September 16 of each year, commencing on September 16, 2015 and ending on the relevant Maturity Date, provided that if
such Interest Payment Date is not a Business Day, the Interest Payment Date shall be postponed to the next Business Day, but interest on that payment will not accrue during the period from and after the scheduled Interest Payment Date. If the
relevant Maturity Date would fall on a day that is not a Business Day, the payment of interest and principal will be made on the next succeeding Business Day, but interest on that payment will not accrue during the period from and after such
Maturity Date.
  
 “Business Day” means any weekday, other than one on which
banking institutions are authorized or obligated by law or executive order to close in London, England or in the City of New York, United States.

		
	Day Count:		30/360, Following, Unadjusted

			
		
	Currency of payment of principal, interest and Additional Amounts:		United States Dollars
		
	Corporate Trust Office:		 The Bank of New York Mellon acting through its London Branch

One Canada Square
 London E14 5AL, United Kingdom

		
	Place of Payment and Paying Agent:		 Corporate Trust Office of the Trustee, London, England.
  

The Bank of New York Mellon acting through its London Branch.

		
	Ranking:		The ranking of the Securities shall be as set forth in the Prospectus Supplement dated March 9, 2015 (the “Prospectus Supplement”).
		
	Regular Record Dates:		The Business Day immediately preceding each relevant Interest Payment Date (or, if the Securities are held in definitive form, the 15th Business Day preceding each relevant Interest Payment Date).
		
	U.K. Bail-In Power Acknowledgment:		No repayment of the Principal Amount of the Securities or payment of interest on the Securities shall become due and payable after the exercise of any U.K. Bail-In Power by the Relevant U.K. Resolution Authority unless such
repayment or payment would be permitted to be made by the Company under the laws and regulations of the United Kingdom and the European Union applicable to the Company.
		
			By its acquisition of the Securities, each Holder and beneficial owner of

			
		
			the Securities acknowledges, agrees to be bound by and consents to the exercise of any U.K. Bail-In Power by the Relevant U.K. Resolution Authority that may result in the cancellation of all, or a portion, of the Principal Amount
of, or interest on, the Securities and/or the conversion of all, or a portion of, the Principal Amount of, or interest on, the Securities into shares or other securities or other obligations of the Company or another person, including by means of a
variation to the terms of the Securities, in each case, to give effect to the exercise by the Relevant U.K. Resolution Authority of such U.K. Bail-In Power. Each Holder and beneficial owner further acknowledges and agrees that the rights of Holders
and beneficial owners of the Securities are subject to, and will be varied, if necessary, so as to give effect to, the exercise of any U.K. Bail-in Power by the Relevant U.K. Resolution Authority.
		
			By its acquisition of the Securities, each Holder and beneficial owner (i) acknowledges and agrees that the exercise of the U.K. Bail-In Power by the Relevant U.K. Resolution Authority with respect to the Securities shall not
give rise to a default for purposes of Section 315(b) (Notice of Default) and Section 315(c) (Duties of the Trustee in Case of Default) of the U.S. Trust Indenture Act of 1939, as amended, (ii) to the extent permitted by the Trust
Indenture Act, waives any and all claims against the Trustee for, agrees

			
		
			not to initiate a suit against the Trustee in respect of, and agrees that the Trustee shall not be liable for, any action that the Trustee takes, or abstains from taking, in either case in accordance with the exercise of the U.K.
Bail-In Power by the Relevant U.K. Resolution Authority with respect to the Securities, (iii) acknowledges and agrees that, upon the exercise of any U.K. Bail-In Power by the Relevant U.K. Resolution Authority, (a) the Trustee shall not be required
to take any further directions from Holders or beneficial owners of the Securities under Section 5.12 of the Indenture and (b) the Indenture shall impose no duties upon the Trustee whatsoever with respect to the exercise of any U.K. Bail-In Power by
the Relevant U.K. Resolution Authority (notwithstanding the foregoing in (iii), if, following the completion of the exercise of the U.K. Bail-In Power by the Relevant U.K. Resolution Authority, the Securities remain outstanding, then the
Trustee’s duties under the Indenture shall remain applicable with respect to the Securities following such completion to the extent that the Company and the Trustee shall agree pursuant to a supplemental indenture), and (iv) shall be deemed to
have (a) consented to the exercise of any U.K. Bail-In Power as it may be imposed without any prior notice by the Relevant U.K. Resolution Authority of its decision to exercise such power with respect to the Securities and (b) authorized, directed
and requested DTC and any

			
		
			direct participant in DTC or other intermediary through which it holds such Securities to take any and all necessary action, if required, to implement the exercise of any U.K. Bail-In Power with respect to the Securities as it may
be imposed, without any further action or direction on the part of such Holder and such beneficial owner or the Trustee.
		
			 Upon the exercise of the U.K. Bail-In Power by the Relevant U.K. Resolution Authority with respect to the Securities, the Company shall
provide a written notice to DTC as soon as practicable regarding such exercise of the U.K. Bail-In Power for purposes of notifying Holders and beneficial owners of such occurrence. The Company shall also deliver a copy of such notice to the Trustee
for information purposes.
  
 The exercise of the U.K. Bail-In Power by the Relevant U.K.
Resolution Authority with respect to the Securities shall not constitute an Event of Default under the Indenture.
  

The Company’s obligations to indemnify the Trustee in accordance with Section 6.07 of the Indenture shall survive any exercise of the U.K. Bail-In
Power by the Relevant U.K. Resolution Authority with respect to the Securities.
  
 Each
Holder and beneficial owner that acquires its Securities in the secondary market shall be deemed to acknowledge and agree to be bound

			
		
			by and consent to the same provisions specified in the provisions above and in the Securities to the same extent as the Holders and beneficial owners of the Securities that acquire the Securities upon their initial issuance,
including, without limitation, with respect to the acknowledgement and agreement to be bound by and consent to the terms of the Securities, including in relation to the U.K. Bail-In Power.
		
			“U.K. Bail-In Power” means any statutory write-down and/or conversion power existing from time to time under any laws, regulations, rules or requirements relating to the resolution of banks, banking group companies, credit
institutions and/or investment firms incorporated in the United Kingdom in effect and applicable in the United Kingdom to the Company or other members of the Group, including but not limited to any such laws, regulations, rules or requirements that
are implemented, adopted or enacted within the context of the European Union directive 2014/59/EU of the European Parliament and of the Council establishing a framework for the recovery and resolution of credit institutions and investment firms of
May 15, 2014, as amended, and/or within the context of a U.K. resolution regime under the U.K. Banking Act 2009, as amended, or otherwise, pursuant to which obligations of a bank, banking group company, credit institution or investment firm or
any of its affiliates can be reduced,

			
		
			 cancelled and/or converted into shares or other securities or obligations of the obligor or any other person (and a reference to the
“Relevant U.K. Resolution Authority” is to any authority with the ability to exercise a U.K. Bail-In Power).
  

“Group” refers to the Company (or any successor entity) and its consolidated subsidiaries.

		
	Early Redemption at the Option of the Company:		 The Securities shall be redeemable prior to the relevant Maturity Date solely pursuant to the terms specified in Section 11.09 of the
Indenture.
  
 For the avoidance of doubt, the provisions of Section 11.08 of the
Indenture shall not apply to the Securities.

		
	Notice of Redemption:		Before the Company may redeem the Securities pursuant to Section 11.09 of the Indenture, the Company shall deliver via DTC (or, if the Securities are definitive Securities, to the Holders at their addresses shown on the Senior Debt
Security Register) prior notice of not less than thirty (30) days, nor more than sixty (60) days, to the Holders of the Securities. The Company shall deliver written notice of such redemption of the Securities to the Trustee at least five (5)
Business Days prior to the date on which the relevant notice of redemption is sent to Holders (unless a shorter notice period shall be satisfactory to the Trustee). The content of such notice shall be in accordance with Section 11.04 of the
Indenture and such notice

			
		
			 shall be irrevocable except in the limited circumstance described in below.

 
 If the Company has delivered a notice of redemption pursuant to this provision, but prior
to the payment of the redemption amount with respect to such redemption the Relevant U.K. Resolution Authority exercises its U.K. Bail-in Power in respect of the Securities, such redemption notice shall be automatically rescinded and shall be of no
force and effect, and no payment in respect of the redemption amount shall be due and payable.
  

If the event specified above occurs, the Company shall promptly deliver notice to the Holders of the Securities via DTC (or, if the Securities are definitive
Securities, to the Holders at their addresses shown on the Senior Debt Security Register) and to the Trustee directly, specifying the occurrence of the relevant event.
  

“DTC” means The Depository Trust Company, or any successor clearing system.

		
	Additional Amounts and FATCA Withholding Tax:		The terms specified in “Payment of Additional Amounts” in the Prospectus Supplement and the section titled “Description of Debt Securities—Payment of Debt Security Additional Amounts” in the Base Prospectus
with respect to Debt Security Additional Amounts (as defined in the Base Prospectus) shall apply to the Securities and shall replace in their entirety the provisions specified in Section 10.04 of the
Indenture.

			
		
			 Any amounts to be paid by the Company or the Paying Agent on the Securities shall be paid net of any deduction or withholding imposed or
required pursuant to Sections 1471 through 1474 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”), any current or future regulations or official interpretations thereof, any agreement entered into pursuant to Section
1471(b) of the Code, or any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement entered into in connection with the implementation of such Sections of the Code (or any law implementing such an
intergovernmental agreement) (a “FATCA Withholding Tax”), and the Company and the Paying Agent shall not be required to pay Additional Amounts on account of any FATCA Withholding Tax.

 
 With respect to the Securities, any Paying Agent shall be entitled to make a deduction or
withholding from any payment which it makes under the Securities and the Indenture for or on account of (i) any present or future taxes, duties or charges if and to the extent so required by any applicable law and (ii) any FATCA Withholding Tax
(together, “Applicable Law”). In either case, the Paying Agent shall make any payment after a deduction or withholding has been made pursuant to Applicable Law and shall

			
		
			 report to the relevant authorities the amount so deducted or withheld. However, such deduction or withholding will not apply to payments made
under the Securities and the Indenture through the relevant clearing systems. In all cases, the Paying Agent shall have no obligation to gross up any payment made subject to any deduction or withholding pursuant to Applicable Law. In addition,
amounts deducted or withheld by the Paying Agent under this paragraph will be treated as paid to the Holder of Securities, and the Company will not pay Additional Amounts in respect of such deduction or withholding, except to the extent the
provisions in this “Additional Amounts and FATCA Withholding Tax” section, the section titled “Payment of Additional Amounts” in the Prospectus Supplement and the section titled “Description of Debt Securities—Payment
of Debt Security Additional Amounts” in the Base Prospectus explicitly provide otherwise.
  

The Company agrees, to the extent the Company has actual knowledge of such information, to provide the Paying Agent with sufficient information about any
modification to the terms of the Securities for the purposes of determining whether FATCA Withholding Tax applies to any payment of principal or interest on the Securities.

		
	Section 3.07 of the Indenture:		Section 3.07 of the Indenture shall apply to the Securities.

			
		
	Subsequent Repurchases:		The Company or any member of the Group may purchase or otherwise acquire any of the Outstanding Securities at any price in the open market or otherwise.
		
	Definitions:		All capitalized terms that are not defined herein shall have the meaning ascribed to such terms in the Indenture.

 EXHIBIT A 

Form of Global Note for the 2018 Notes 

THIS SECURITY IS A GLOBAL REGISTERED SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A
NOMINEE THEREOF. THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF,
EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 
 This Security is one of a duly authorized issue of securities of the Company (as defined
below) (herein called the “Securities” and each, a “Security”) issued and to be issued in one or more series under and governed by the Senior Debt Securities Indenture, dated as of November 10, 2014 (the
“Indenture”), and under an Officer’s Certificate pursuant to Sections 1.02, 3.01 and 3.03 of the Indenture dated March 16, 2015 (the “Officer’s Certificate”). 

The exercise of any U.K. Bail-In Power by the Relevant U.K. Resolution Authority may result in the (i) cancellation of all, or a portion, of the
principal amount of, or interest on, the Securities and/or (ii) the conversion of all, or a portion of, the principal amount of, or interest on, the Securities into shares or other securities or other obligations of the Company or another
person, including by means of a variation to the terms of the Securities, in each case, to give effect to the exercise by the Relevant U.K. Resolution Authority of such U.K. Bail-In Power. The rights of Holders and beneficial owners of the
Securities are subject to, and will be varied, if necessary, so as to give effect to, the exercise of any U.K. Bail-in Power by the Relevant U.K. Resolution Authority. 

 BARCLAYS PLC 

US$ 1,000,000,000 2.00% Fixed Rate Senior Notes due 2018 
  

									
	No. [    ]								$[            ]

 CUSIP NO. 06738EAF2 

ISIN NO. US06738EAF25 
 BARCLAYS
PLC, a company duly incorporated and existing under the laws of England and Wales (herein called the “Company”, which term includes any successor Person under the Indenture hereinafter referred to), for value received, hereby
promises to pay to Cede & Co., or registered assigns, the principal sum of US$ [            ] on March 16, 2018 (the “Maturity Date”), except as otherwise
provided herein, and to pay interest thereon, in accordance with the terms hereof. Interest shall accrue on this Security from March 16, 2015 or from the most recent Interest Payment Date (as defined below) to which interest has been paid or
duly provided for, and shall be paid semi-annually in arrear on September 16 and March 16 of each year (each, an “Interest Payment Date”), commencing on September 16, 2015 and ending on the Maturity Date, except as
otherwise provided herein, at the rate of 2.00% per annum, until the principal hereof is paid or made available for payment. 
 If any
Interest Payment Date is not a Business Day, the Interest Payment Date shall be postponed to the next Business Day, and no further interest or other payment shall be owed or made in respect of such delay. If the Maturity Date would fall on a day
that is not a Business Day, the payment of interest and principal will be made on the next succeeding Business Day, but interest on that payment will not accrue during the period from and after such Maturity Date. If a date of redemption is not a
Business Day, the Company may pay interest (if any) and principal on the next succeeding Business Day, but interest on that payment will not accrue during the period from and after the date of redemption. A “Business Day” means any
weekday, other than one on which banking institutions are authorized or obligated by law or executive order to close in London, England or in the City of New York, United States. 

Subject to the limitations specified on the reverse of this Security, interest on the Securities shall be computed and payable in arrear and
on the basis of a year of 360 days consisting of twelve (12) months of thirty (30) days each and, in the case of an incomplete month, the actual number of days elapsed. 

The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in the Indenture, be paid to
the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on the Regular Record Date for such interest which shall be the Business Day immediately preceding each Interest Payment Date (or,
if the Securities are held in definitive form, the 15th Business Day preceding each Interest Payment Date). Any such interest not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular Record Date
and may either be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on a Special Record Date for the payment of 

 
such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this series not less than 10 days prior to such Special Record Date, or be paid
at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon such notice as may be required by such exchange, all as more fully provided in
said Indenture. 
 No repayment of the principal amount of the Securities or payment of interest on the Securities shall become due and
payable after the exercise of any U.K. Bail-In Power by the Relevant U.K. Resolution Authority unless such repayment or payment would be permitted to be made by the Company under the laws and regulations of the United Kingdom and the European Union
applicable to the Company. 
 Payments of principal of and interest, if any, on the Securities shall be made in such coin or currency of the
United States of America as at the time of payment is legal tender for payment of public and private debts and such payments shall be made through one or more Paying Agents appointed under the Indenture to the Holder or Holders of this Security.
Initially, the Paying Agent and the Senior Debt Security Registrar for the Securities shall be The Bank of New York Mellon acting through its London Branch, One Canada Square, London E14 5AL, United Kingdom and the Place of Payment in respect of the
Securities shall be the Corporate Trust Office of the Trustee, which as of the date hereof is the office or agency of the Trustee located at said address. The Company may change the Paying Agent or, subject to Section 3.01 of the Indenture, the
Place of Payment without prior notice to the Holders of the Securities, and in such an event the Company may act as Paying Agent or Security Registrar. Payments of principal of and interest on the Securities shall be made by wire transfer of
immediately available funds; provided, however, that in the case of payments of principal, this Security is first surrendered to the Paying Agent. 

This Security shall be governed by and construed in accordance with the laws of the State of New York. 

Reference is hereby made to the further provisions of this Security set forth on the reverse hereof, which further provisions shall for all
purposes have the same effect as if set forth at this place. 
 All terms used in this Security which are defined in the Indenture shall
have the meanings assigned to them in the Indenture, as defined herein. 
 THIS SECURITY IS NOT A DEPOSIT AND IS NOT INSURED BY THE UNITED
STATES FEDERAL DEPOSIT INSURANCE CORPORATION OR ANY OTHER GOVERNMENT AGENCY OF THE UNITED STATES OR THE UNITED KINGDOM. 
 Unless the
certificate of authentication hereon has been executed by the Trustee referred to on the reverse hereof, directly or through an Authenticating Agent, by manual signature of an authorized signatory, this Security shall not be entitled to any benefit
under the Indenture or be valid or obligatory for any purpose. 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed. 

 

							
	Dated: March 16, 2015				BARCLAYS PLC
				
					By:		  

					Name:		
					Title:		
				
					By:		  

					Name:		
					Title:		

 Trustee’s Certificate of Authentication 

This is one of the Securities of the series designated herein referred to in the Indenture. 

 

							
	Dated: March 16, 2015				THE BANK OF NEW YORK MELLON, LONDON BRANCH
					            As Trustee
				
					By:		  

							Authorized Signatory

 Signature Page to Global Note [—] 

 (Reverse of Security) 

This Security is one of a duly authorized issue of securities of the Company (herein called the “Securities” and each, a
“Security”) issued and to be issued in one or more series under and governed by the Senior Debt Securities Indenture, dated as of November 10, 2014 (herein called the “Indenture”), between the Company and The
Bank of New York Mellon acting through its London Branch, as Trustee (herein called the “Trustee,” which term includes any successor trustee under the Indenture) and under an Officer’s Certificate pursuant to Sections 1.02,
3.01 and 3.03 of the Indenture dated March 16, 2015 (the “Officer’s Certificate”), and reference is hereby made to the Indenture, the terms of which are incorporated herein by reference, for a statement of the respective rights,
limitations of rights, duties and immunities thereunder of the Company, the Trustee, the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered. Insofar as the provisions of the Indenture
and the Officer’s Certificate may conflict with the provisions set forth in this Security, the former shall control for purposes of this Security. 

This Security is one of the series designated on the face hereof, limited to an aggregate principal amount of US$1,000,000,000, which amount
may be increased at the option of the Company if in the future it determines that it may wish to sell additional Securities of this series. References herein to “this series” mean the series designated on the face hereof. 

For purposes of this Security: 

“DTC” means The Depository Trust Company, or any successor clearing system. 

“Group” refers to the Company (or any successor entity) and its consolidated subsidiaries. 

“U.K. Bail-In Power” means any statutory write-down and/or conversion power existing from time to time under any laws,
regulations, rules or requirements relating to the resolution of banks, banking group companies, credit institutions and/or investment firms incorporated in the United Kingdom in effect and applicable in the United Kingdom to the Company or other
members of the Group, including but not limited to any such laws, regulations, rules or requirements that are implemented, adopted or enacted within the context of the European Union directive 2014/59/EU of the European Parliament and of the Council
establishing a framework for the recovery and resolution of credit institutions and investment firms of May 15, 2014, and/or within the context of a U.K. resolution regime under the U.K. Banking Act 2009, as amended, or otherwise, pursuant to
which obligations of a bank, banking group company, credit institution or investment firm or any of its affiliates can be reduced, cancelled and/or converted into shares or other securities or obligations of the obligor or any other person (and a
reference to the “Relevant U.K. Resolution Authority” is to any authority with the ability to exercise a U.K. Bail-In Power). 

 Any amounts to be paid by the Company on the Securities shall be made without deduction or
withholding for, or on account of, any and all present or future income, stamp and other taxes, levies, imposts, duties, charges, fees, deductions or withholdings (“Taxes”) now or hereafter imposed, levied, collected, withheld or
assessed by, or on behalf of, the United Kingdom or any U.K. political subdivision or authority thereof or therein having the power to tax (each a “Taxing Jurisdiction”), unless such deduction or withholding is required by law. If
any such Taxes shall at any time be required by any Taxing Jurisdiction to be deducted or withheld, the Company shall, subject to the exceptions and limitations set forth herein, pay such additional amounts of, or in respect of, the principal of,
and any interest on, the Securities (“Additional Amounts”) as may be necessary in order that the net amounts paid to the Holders of the Securities, after such deduction or withholding, shall equal the respective amounts of principal
and interest that would have been payable in respect of such Securities had no such deduction or withholding been required. 
 Any amounts
to be paid by the Company or the Paying Agent on the Securities shall be paid net of any deduction or withholding imposed or required pursuant to Sections 1471 through 1474 of the U.S. Internal Revenue Code of 1986, as amended (the
“Code”), any current or future regulations or official interpretations thereof, any agreement entered into pursuant to Section 1471(b) of the Code, or any fiscal or regulatory legislation, rules or practices adopted pursuant to
any intergovernmental agreement entered into in connection with the implementation of such Sections of the Code (or any law implementing such an intergovernmental agreement) (a “FATCA Withholding Tax”), and neither the Company nor
the Paying Agent shall be required to pay Additional Amounts on account of any FATCA Withholding Tax. 
 Any Paying Agent shall be entitled
to make a deduction or withholding from any payment which it makes under the Securities and the Indenture for or on account of (i) any present or future taxes, duties or charges if and to the extent so required by any applicable law and
(ii) any FATCA Withholding Tax (together, “Applicable Law”). In either case, the Paying Agent shall make any payment after a deduction or withholding has been made pursuant to Applicable Law and shall report to the relevant
authorities the amount so deducted or withheld. However, such deduction or withholding will not apply to payments made under the Securities and the Indenture through the relevant clearing systems. In all cases, the Paying Agent shall have no
obligation to gross up any payment made subject to any deduction or withholding pursuant to Applicable Law. In addition, amounts deducted or withheld by the Paying Agent as described in this paragraph will be treated as paid to the Holder of the
Securities, and the Company will not pay Additional Amounts in respect of such deduction or withholding, except to the extent the provisions in this paragraph explicitly provide otherwise. 

The Company agrees, to the extent the Company has actual knowledge of such information, to provide the Paying Agent with sufficient
information about any modification to the terms of the Securities for the purposes of determining whether FATCA Withholding Tax applies to any payment of principal or interest on the Securities. 

 The Company may, at any time, at the Company’s option, redeem the Securities, in whole but
not in part at a redemption price equal to 100% of the principal amount of the Securities then Outstanding, together with any accrued but unpaid interest to (but excluding) the date fixed for redemption, if the Company determines that as a result of
a change in, or amendment to, the laws or regulations of any Taxing Jurisdiction, including any treaty to which the relevant Taxing Jurisdiction is a party, or a change in an official application or interpretation of those laws or regulations on or
after the Issue Date, including any decision of any court or tribunal, which becomes effective on or after the Issue Date (and, in the case of a successor entity, which becomes effective on or after the date of such successor entity’s
assumption of the Company’s obligations): (a) the Company will or would be required to pay Additional Amounts to Holders of the Securities, (b) the Company would not be entitled to claim a deduction in respect of any payments in
computing the Company’s taxation liabilities or the amount of the deduction would be materially reduced, or (c) the Company would not, as a result of the Securities being in issue, be able to have the losses or deductions set against the
profits or gains, or profits or gains offset by the losses or deductions, of companies with which the Company is or would otherwise be so grouped for applicable United Kingdom tax purposes (whether under the group relief system current as at the
Issue Date, or any similar system or systems having like effect as may from time to time exist), (each of (a), (b) and (c) above, a “Tax Event”); provided, however, that the Securities may only be redeemed pursuant to this
paragraph if, in the case of each Tax Event, the consequences of the Tax Event cannot be avoided by the Company taking reasonable measures available to the Company. 

Prior to the delivery of any notice of redemption, the Company shall deliver to the Trustee an opinion of independent counsel of recognized
standing, chosen by the Company, in a form satisfactory to the Trustee confirming that the Company is entitled to exercise its right of redemption under Section 11.09 of the Indenture. 

Before the Company may redeem the Securities pursuant to any of the preceding paragraphs relating to the Company’s rights of redemption,
the Company shall deliver prior notice of not less than thirty (30) days, nor more than sixty (60) days to the Holders of the Securities. The Company shall deliver written notice of such redemption of the Securities to the Trustee at least
five (5) Business Days prior to the date on which the relevant notice of redemption is sent to Holders (unless a shorter notice period shall be satisfactory to the Trustee). Such notice shall specify the Company’s election to redeem the
Securities and the date fixed for such redemption and shall be irrevocable except in the limited circumstances described in this paragraph. If the Company has delivered a notice of redemption pursuant to this paragraph, but prior to the payment of
the redemption amount with respect to such redemption the Relevant U.K. Resolution Authority exercises its U.K. Bail-in Power in respect of the Securities, such redemption notice shall be automatically rescinded and shall be of no force and effect,
and no payment in respect of the redemption amount shall be due and payable. If the event 

 
specified in the preceding sentence occurs, the Company shall promptly deliver notice to the Holders of the Securities via DTC and to the Trustee directly, specifying the occurrence of the
relevant event. 
 The Company or any member of the Group may purchase or otherwise acquire any of the Outstanding Securities at any price
in the open market or otherwise. 
 All authority conferred or agreed to be conferred by each Holder and beneficial owner pursuant to this
Security, including the consents given by such Holder and beneficial owner, shall be binding upon the successors, assigns, heirs, executors, administrators, trustees in bankruptcy and legal representatives of such Holder and beneficial owner. 

By its acquisition of the Securities, each Holder and beneficial owner of the Securities acknowledges, agrees to be bound by and consents to
the exercise of any U.K. Bail-In Power by the Relevant U.K. Resolution Authority that may result in the cancellation of all, or a portion, of the principal amount of, or interest on, the Securities and/or the conversion of all, or a portion of, the
principal amount of, or interest on, the Securities into shares or other securities or other obligations of the Company or another person, including by means of a variation to the terms of the Securities, in each case, to give effect to the exercise
by the Relevant U.K. Resolution Authority of such U.K. Bail-In Power. Each Holder and beneficial owner further acknowledges and agrees that the rights of Holders and beneficial owners of the Securities are subject to, and will be varied, if
necessary, so as to give effect to, the exercise of any U.K. Bail-in Power by the Relevant U.K. Resolution Authority. 
 By its acquisition
of the Securities, each Holder and beneficial owner (i) acknowledges and agrees that the exercise of the U.K. Bail-In Power by the Relevant U.K. Resolution Authority with respect to the Securities shall not give rise to a default for purposes
of Section 315(b) (Notice of Default) and Section 315(c) (Duties of the Trustee in Case of Default) of the U.S. Trust Indenture Act of 1939, as amended, (ii) to the extent permitted by the Trust Indenture Act, waives any
and all claims against the Trustee for, agrees not to initiate a suit against the Trustee in respect of, and agrees that the Trustee shall not be liable for, any action that the Trustee takes, or abstains from taking, in either case in accordance
with the exercise of the U.K. Bail-In Power by the Relevant U.K. Resolution Authority with respect to the Securities, (iii) acknowledges and agrees that, upon the exercise of any U.K. Bail-In Power by the Relevant U.K. Resolution Authority,
(a) the Trustee shall not be required to take any further directions from Holders or beneficial owners of the Securities under Section 5.12 of the Indenture and (b) the Indenture shall impose no duties upon the Trustee whatsoever with
respect to the exercise of any U.K. Bail-In Power by the Relevant U.K. Resolution Authority (notwithstanding the foregoing in this clause (iii), if, following the completion of the exercise of the U.K. Bail-In Power by the Relevant U.K. Resolution
Authority, the Securities remain outstanding, then the Trustee’s duties under the Indenture shall remain applicable with respect to the Securities following such completion to the extent that the Company and

 
the Trustee shall agree pursuant to a supplemental indenture), and (iv) shall be deemed to have (a) consented to the exercise of any U.K. Bail-In Power as it may be imposed without any
prior notice by the Relevant U.K. Resolution Authority of its decision to exercise such power with respect to the Securities and (b) authorized, directed and requested DTC and any direct participant in DTC or other intermediary through which it
holds such Securities to take any and all necessary action, if required, to implement the exercise of any U.K. Bail-In Power with respect to the Securities as it may be imposed, without any further action or direction on the part of such Holder and
such beneficial owner or the Trustee. 
 Each Holder and Beneficial Owner that acquires its Securities in the secondary market shall be
deemed to acknowledge and agree to be bound by and consent to the same provisions specified in the Indenture to the same extent as the Holders and Beneficial Owners of the Securities that acquire the Securities upon their initial issuance,
including, without limitation, with respect to the acknowledgement and agreement to be bound by and consent to the terms of the Securities, including in relation to the U.K. Bail-In Power. 

Upon the exercise of the U.K. Bail-In Power by the Relevant U.K. Resolution Authority with respect to the Securities, the Company shall
provide a written notice to DTC as soon as practicable regarding such exercise of the U.K. Bail-In Power for purposes of notifying Holders and beneficial owners of such occurrence. The Company shall also deliver a copy of such notice to the Trustee
for information purposes. 
 The Company’s obligations to indemnify the Trustee in accordance with Section 6.07 of the Indenture
shall survive any exercise of the U.K. Bail-In Power by the Relevant U.K. Resolution Authority with respect to the Securities. 
 The
exercise of the U.K. Bail-In Power by the Relevant U.K. Resolution Authority with respect to the Securities shall not constitute an Event of Default under the Indenture. 

The Securities shall constitute the Company’s direct, unconditional, unsecured and unsubordinated obligations and shall at all times rank
pari passu among themselves. In the event of a winding-up or administration of the Company, the Securities shall rank pari passu with all other outstanding unsecured and unsubordinated obligations of the Company, present and future,
except such obligations as are preferred by operation of law. 
 The Indenture permits, with certain exceptions as therein provided, the
amendment thereof and the modification of the rights and obligations of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the
Holders of not less than a majority in aggregate in principal amount of the Securities then Outstanding of each series to be affected. The Indenture also contains provisions 

 
permitting the Holders of a majority in aggregate principal amount of the Securities of each series then Outstanding, on behalf of the Holders of all Securities of such series, to waive
compliance by the Company with certain provisions of the Indenture and certain past Event of Defaults under the Indenture and their consequences. Any such consent or waiver by the Holder of this Security shall be conclusive and binding upon such
Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Security. 

As provided in and subject to the provisions of the Indenture, the Holder of this Security shall not have any right to institute any
proceeding, judicial or otherwise, with respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy thereunder, unless such Holder shall have previously given the Trustee written notice of a continuing Event of
Default with respect to the Securities of this series, the Holders of not less than 25% in aggregate principal amount of the Securities of this series then Outstanding shall have made written request to the Trustee to institute proceedings in
respect of such Event of Default as Trustee and offered to the Trustee security or indemnity satisfactory to the Trustee in its sole discretion against the costs, expenses and liabilities to be incurred in compliance with such request, the Trustee
shall not have received from the Holders of a majority in principal amount of Securities of this series then Outstanding a direction inconsistent with such request, and shall have failed to institute any such proceeding, for sixty (60) days
after receipt of such notice, request and offer of indemnity. 
 Notwithstanding any contrary provisions in this Security, nothing shall
impair the right of a Holder of this Security under the Trust Indenture Act, absent such Holder’s consent, to sue for any payments due but unpaid with respect to this Security. 

As provided in the Indenture and subject to certain limitations therein set forth, the transfer of this Security is registrable in the Senior
Debt Security Register, upon surrender of this Security for registration of transfer at the office or agency of the Company in any place where the principal of this Security is payable, duly endorsed by, or accompanied by a written instrument of
transfer in form satisfactory to the Company and the Senior Debt Security Registrar duly executed by, the Holder hereof or his attorney duly authorized in writing. Thereupon one or more new Securities of this series and of like tenor, of authorized
denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees. 
 This Security, and
any other Securities of this series and of like tenor, are issuable only in registered form without coupons in initial denominations of $200,000 and increments of $1,000 thereafter. The denominations cannot be changed without the consent of the
Trustee. 

 No service charge shall be made for any such registration of transfer or exchange, but the
Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. 
 Prior to
due presentment of this Security for registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not
this Security be overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the contrary. 
 This
Security shall be governed by and construed in accordance with the laws of the State of New York. 

 EXHIBIT B 

Form of Global Note for the 2025 Notes 

THIS SECURITY IS A GLOBAL REGISTERED SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A
NOMINEE THEREOF. THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF,
EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 
 This Security is one of a duly authorized issue of securities of the Company (as defined
below) (herein called the “Securities” and each, a “Security”) issued and to be issued in one or more series under and governed by the Senior Debt Securities Indenture, dated as of November 10, 2014 (the
“Indenture”), and under an Officer’s Certificate pursuant to Sections 1.02, 3.01 and 3.03 of the Indenture dated March 16, 2015 (the “Officer’s Certificate”). 

The exercise of any U.K. Bail-In Power by the Relevant U.K. Resolution Authority may result in the (i) cancellation of all, or a portion, of the
principal amount of, or interest on, the Securities and/or (ii) the conversion of all, or a portion of, the principal amount of, or interest on, the Securities into shares or other securities or other obligations of the Company or another
person, including by means of a variation to the terms of the Securities, in each case, to give effect to the exercise by the Relevant U.K. Resolution Authority of such U.K. Bail-In Power. The rights of Holders and beneficial owners of the
Securities are subject to, and will be varied, if necessary, so as to give effect to, the exercise of any U.K. Bail-in Power by the Relevant U.K. Resolution Authority. 

 BARCLAYS PLC 

US$ 2,000,000,000 3.65% Fixed Rate Senior Notes due 2025 
  

									
	No. [    ]								$[            ]

 CUSIP NO. 06738EAE5 

ISIN NO. US06738EAE59 
 BARCLAYS
PLC, a company duly incorporated and existing under the laws of England and Wales (herein called the “Company”, which term includes any successor Person under the Indenture hereinafter referred to), for value received, hereby
promises to pay to Cede & Co., or registered assigns, the principal sum of US$ [            ] on March 16, 2025 (the “Maturity Date”), except as otherwise
provided herein, and to pay interest thereon, in accordance with the terms hereof. Interest shall accrue on this Security from March 16, 2015 or from the most recent Interest Payment Date (as defined below) to which interest has been paid or
duly provided for, and shall be paid semi-annually in arrear on September 16 and March 16 of each year (each, an “Interest Payment Date”), commencing on September 16, 2015 and ending on the Maturity Date, except as
otherwise provided herein, at the rate of 3.65% per annum, until the principal hereof is paid or made available for payment. 
 If any
Interest Payment Date is not a Business Day, the Interest Payment Date shall be postponed to the next Business Day, and no further interest or other payment shall be owed or made in respect of such delay. If the Maturity Date would fall on a day
that is not a Business Day, the payment of interest and principal will be made on the next succeeding Business Day, but interest on that payment will not accrue during the period from and after such Maturity Date. If a date of redemption is not a
Business Day, the Company may pay interest (if any) and principal on the next succeeding Business Day, but interest on that payment will not accrue during the period from and after the date of redemption. A “Business Day” means any
weekday, other than one on which banking institutions are authorized or obligated by law or executive order to close in London, England or in the City of New York, United States. 

Subject to the limitations specified on the reverse of this Security, interest on the Securities shall be computed and payable in arrear and
on the basis of a year of 360 days consisting of twelve (12) months of thirty (30) days each and, in the case of an incomplete month, the actual number of days elapsed. 

The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in the Indenture, be paid to
the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on the Regular Record Date for such interest which shall be the Business Day immediately preceding each Interest Payment Date (or,
if the Securities are held in definitive form, the 15th Business Day preceding each Interest Payment Date). Any such interest not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular Record Date
and may either be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on a Special Record Date for the payment of 

 
such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this series not less than 10 days prior to such Special Record Date, or be paid
at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon such notice as may be required by such exchange, all as more fully provided in
said Indenture. 
 No repayment of the principal amount of the Securities or payment of interest on the Securities shall become due and
payable after the exercise of any U.K. Bail-In Power by the Relevant U.K. Resolution Authority unless such repayment or payment would be permitted to be made by the Company under the laws and regulations of the United Kingdom and the European Union
applicable to the Company. 
 Payments of principal of and interest, if any, on the Securities shall be made in such coin or currency of the
United States of America as at the time of payment is legal tender for payment of public and private debts and such payments shall be made through one or more Paying Agents appointed under the Indenture to the Holder or Holders of this Security.
Initially, the Paying Agent and the Senior Debt Security Registrar for the Securities shall be The Bank of New York Mellon acting through its London Branch, One Canada Square, London E14 5AL, United Kingdom and the Place of Payment in respect of the
Securities shall be the Corporate Trust Office of the Trustee, which as of the date hereof is the office or agency of the Trustee located at said address. The Company may change the Paying Agent or, subject to Section 3.01 of the Indenture, the
Place of Payment without prior notice to the Holders of the Securities, and in such an event the Company may act as Paying Agent or Security Registrar. Payments of principal of and interest on the Securities shall be made by wire transfer of
immediately available funds; provided, however, that in the case of payments of principal, this Security is first surrendered to the Paying Agent. 

This Security shall be governed by and construed in accordance with the laws of the State of New York. 

Reference is hereby made to the further provisions of this Security set forth on the reverse hereof, which further provisions shall for all
purposes have the same effect as if set forth at this place. 
 All terms used in this Security which are defined in the Indenture shall
have the meanings assigned to them in the Indenture, as defined herein. 
 THIS SECURITY IS NOT A DEPOSIT AND IS NOT INSURED BY THE UNITED
STATES FEDERAL DEPOSIT INSURANCE CORPORATION OR ANY OTHER GOVERNMENT AGENCY OF THE UNITED STATES OR THE UNITED KINGDOM. 
 Unless the
certificate of authentication hereon has been executed by the Trustee referred to on the reverse hereof, directly or through an Authenticating Agent, by manual signature of an authorized signatory, this Security shall not be entitled to any benefit
under the Indenture or be valid or obligatory for any purpose. 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed. 

 

							
	Dated: March 16, 2015				BARCLAYS PLC
				
					By:		  

					Name:		
					Title:		
				
					By:		  

					Name:		
					Title:		

 Trustee’s Certificate of Authentication 

This is one of the Securities of the series designated herein referred to in the Indenture. 

 

							
	Dated: March 16, 2015				THE BANK OF NEW YORK MELLON, LONDON BRANCH
					            As Trustee
				
					By:		  

							Authorized Signatory

 Signature Page to Global Note [—] 

 (Reverse of Security) 

This Security is one of a duly authorized issue of securities of the Company (herein called the “Securities” and each, a
“Security”) issued and to be issued in one or more series under and governed by the Senior Debt Securities Indenture, dated as of November 10, 2014 (herein called the “Indenture”), between the Company and The
Bank of New York Mellon acting through its London Branch, as Trustee (herein called the “Trustee,” which term includes any successor trustee under the Indenture) and under an Officer’s Certificate pursuant to Sections 1.02,
3.01 and 3.03 of the Indenture dated March 16, 2015 (the “Officer’s Certificate”), and reference is hereby made to the Indenture, the terms of which are incorporated herein by reference, for a statement of the respective rights,
limitations of rights, duties and immunities thereunder of the Company, the Trustee, the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered. Insofar as the provisions of the Indenture
and the Officer’s Certificate may conflict with the provisions set forth in this Security, the former shall control for purposes of this Security. 

This Security is one of the series designated on the face hereof, limited to an aggregate principal amount of US$2,000,000,000, which amount
may be increased at the option of the Company if in the future it determines that it may wish to sell additional Securities of this series. References herein to “this series” mean the series designated on the face hereof. 

For purposes of this Security: 

“DTC” means The Depository Trust Company, or any successor clearing system. 

“Group” refers to the Company (or any successor entity) and its consolidated subsidiaries. 

“U.K. Bail-In Power” means any statutory write-down and/or conversion power existing from time to time under any laws,
regulations, rules or requirements relating to the resolution of banks, banking group companies, credit institutions and/or investment firms incorporated in the United Kingdom in effect and applicable in the United Kingdom to the Company or other
members of the Group, including but not limited to any such laws, regulations, rules or requirements that are implemented, adopted or enacted within the context of the European Union directive 2014/59/EU of the European Parliament and of the Council
establishing a framework for the recovery and resolution of credit institutions and investment firms of May 15, 2014, and/or within the context of a U.K. resolution regime under the U.K. Banking Act 2009, as amended, or otherwise, pursuant to
which obligations of a bank, banking group company, credit institution or investment firm or any of its affiliates can be reduced, cancelled and/or converted into shares or other securities or obligations of the obligor or any other person (and a
reference to the “Relevant U.K. Resolution Authority” is to any authority with the ability to exercise a U.K. Bail-In Power). 

 Any amounts to be paid by the Company on the Securities shall be made without deduction or
withholding for, or on account of, any and all present or future income, stamp and other taxes, levies, imposts, duties, charges, fees, deductions or withholdings (“Taxes”) now or hereafter imposed, levied, collected, withheld or
assessed by, or on behalf of, the United Kingdom or any U.K. political subdivision or authority thereof or therein having the power to tax (each a “Taxing Jurisdiction”), unless such deduction or withholding is required by law. If
any such Taxes shall at any time be required by any Taxing Jurisdiction to be deducted or withheld, the Company shall, subject to the exceptions and limitations set forth herein, pay such additional amounts of, or in respect of, the principal of,
and any interest on, the Securities (“Additional Amounts”) as may be necessary in order that the net amounts paid to the Holders of the Securities, after such deduction or withholding, shall equal the respective amounts of principal
and interest that would have been payable in respect of such Securities had no such deduction or withholding been required. 
 Any amounts
to be paid by the Company or the Paying Agent on the Securities shall be paid net of any deduction or withholding imposed or required pursuant to Sections 1471 through 1474 of the U.S. Internal Revenue Code of 1986, as amended (the
“Code”), any current or future regulations or official interpretations thereof, any agreement entered into pursuant to Section 1471(b) of the Code, or any fiscal or regulatory legislation, rules or practices adopted pursuant to
any intergovernmental agreement entered into in connection with the implementation of such Sections of the Code (or any law implementing such an intergovernmental agreement) (a “FATCA Withholding Tax”), and neither the Company nor
the Paying Agent shall be required to pay Additional Amounts on account of any FATCA Withholding Tax. 
 Any Paying Agent shall be entitled
to make a deduction or withholding from any payment which it makes under the Securities and the Indenture for or on account of (i) any present or future taxes, duties or charges if and to the extent so required by any applicable law and
(ii) any FATCA Withholding Tax (together, “Applicable Law”). In either case, the Paying Agent shall make any payment after a deduction or withholding has been made pursuant to Applicable Law and shall report to the relevant
authorities the amount so deducted or withheld. However, such deduction or withholding will not apply to payments made under the Securities and the Indenture through the relevant clearing systems. In all cases, the Paying Agent shall have no
obligation to gross up any payment made subject to any deduction or withholding pursuant to Applicable Law. In addition, amounts deducted or withheld by the Paying Agent as described in this paragraph will be treated as paid to the Holder of the
Securities, and the Company will not pay Additional Amounts in respect of such deduction or withholding, except to the extent the provisions in this paragraph explicitly provide otherwise. 

The Company agrees, to the extent the Company has actual knowledge of such information, to provide the Paying Agent with sufficient
information about any modification to the terms of the Securities for the purposes of determining whether FATCA Withholding Tax applies to any payment of principal or interest on the Securities. 

 The Company may, at any time, at the Company’s option, redeem the Securities, in whole but
not in part at a redemption price equal to 100% of the principal amount of the Securities then Outstanding, together with any accrued but unpaid interest to (but excluding) the date fixed for redemption, if the Company determines that as a result of
a change in, or amendment to, the laws or regulations of any Taxing Jurisdiction, including any treaty to which the relevant Taxing Jurisdiction is a party, or a change in an official application or interpretation of those laws or regulations on or
after the Issue Date, including any decision of any court or tribunal, which becomes effective on or after the Issue Date (and, in the case of a successor entity, which becomes effective on or after the date of such successor entity’s
assumption of the Company’s obligations): (a) the Company will or would be required to pay Additional Amounts to Holders of the Securities, (b) the Company would not be entitled to claim a deduction in respect of any payments in
computing the Company’s taxation liabilities or the amount of the deduction would be materially reduced, or (c) the Company would not, as a result of the Securities being in issue, be able to have the losses or deductions set against the
profits or gains, or profits or gains offset by the losses or deductions, of companies with which the Company is or would otherwise be so grouped for applicable United Kingdom tax purposes (whether under the group relief system current as at the
Issue Date, or any similar system or systems having like effect as may from time to time exist), (each of (a), (b) and (c) above, a “Tax Event”); provided, however, that the Securities may only be redeemed pursuant to this
paragraph if, in the case of each Tax Event, the consequences of the Tax Event cannot be avoided by the Company taking reasonable measures available to the Company. 

Prior to the delivery of any notice of redemption, the Company shall deliver to the Trustee an opinion of independent counsel of recognized
standing, chosen by the Company, in a form satisfactory to the Trustee confirming that the Company is entitled to exercise its right of redemption under Section 11.09 of the Indenture. 

Before the Company may redeem the Securities pursuant to any of the preceding paragraphs relating to the Company’s rights of redemption,
the Company shall deliver prior notice of not less than thirty (30) days, nor more than sixty (60) days to the Holders of the Securities. The Company shall deliver written notice of such redemption of the Securities to the Trustee at least
five (5) Business Days prior to the date on which the relevant notice of redemption is sent to Holders (unless a shorter notice period shall be satisfactory to the Trustee). Such notice shall specify the Company’s election to redeem the
Securities and the date fixed for such redemption and shall be irrevocable except in the limited circumstances described in this paragraph. If the Company has delivered a notice of redemption pursuant to this paragraph, but prior to the payment of
the redemption amount with respect to such redemption the Relevant U.K. Resolution Authority exercises its U.K. Bail-in Power in respect of the Securities, such redemption notice shall be automatically rescinded and shall be of no force and effect,
and no payment in respect of the redemption amount shall be due and payable. If the event 

 
specified in the preceding sentence occurs, the Company shall promptly deliver notice to the Holders of the Securities via DTC and to the Trustee directly, specifying the occurrence of the
relevant event. 
 The Company or any member of the Group may purchase or otherwise acquire any of the Outstanding Securities at any price
in the open market or otherwise. 
 All authority conferred or agreed to be conferred by each Holder and beneficial owner pursuant to this
Security, including the consents given by such Holder and beneficial owner, shall be binding upon the successors, assigns, heirs, executors, administrators, trustees in bankruptcy and legal representatives of such Holder and beneficial owner. 

By its acquisition of the Securities, each Holder and beneficial owner of the Securities acknowledges, agrees to be bound by and consents to
the exercise of any U.K. Bail-In Power by the Relevant U.K. Resolution Authority that may result in the cancellation of all, or a portion, of the principal amount of, or interest on, the Securities and/or the conversion of all, or a portion of, the
principal amount of, or interest on, the Securities into shares or other securities or other obligations of the Company or another person, including by means of a variation to the terms of the Securities, in each case, to give effect to the exercise
by the Relevant U.K. Resolution Authority of such U.K. Bail-In Power. Each Holder and beneficial owner further acknowledges and agrees that the rights of Holders and beneficial owners of the Securities are subject to, and will be varied, if
necessary, so as to give effect to, the exercise of any U.K. Bail-in Power by the Relevant U.K. Resolution Authority. 
 By its acquisition
of the Securities, each Holder and beneficial owner (i) acknowledges and agrees that the exercise of the U.K. Bail-In Power by the Relevant U.K. Resolution Authority with respect to the Securities shall not give rise to a default for purposes
of Section 315(b) (Notice of Default) and Section 315(c) (Duties of the Trustee in Case of Default) of the U.S. Trust Indenture Act of 1939, as amended, (ii) to the extent permitted by the Trust Indenture Act, waives any
and all claims against the Trustee for, agrees not to initiate a suit against the Trustee in respect of, and agrees that the Trustee shall not be liable for, any action that the Trustee takes, or abstains from taking, in either case in accordance
with the exercise of the U.K. Bail-In Power by the Relevant U.K. Resolution Authority with respect to the Securities, (iii) acknowledges and agrees that, upon the exercise of any U.K. Bail-In Power by the Relevant U.K. Resolution Authority,
(a) the Trustee shall not be required to take any further directions from Holders or beneficial owners of the Securities under Section 5.12 of the Indenture and (b) the Indenture shall impose no duties upon the Trustee whatsoever with
respect to the exercise of any U.K. Bail-In Power by the Relevant U.K. Resolution Authority (notwithstanding the foregoing in this clause (iii), if, following the completion of the exercise of the U.K. Bail-In Power by the Relevant U.K. Resolution
Authority, the Securities remain outstanding, then the Trustee’s duties under the Indenture shall remain applicable with respect to the Securities following such completion to the extent that the Company and

 
the Trustee shall agree pursuant to a supplemental indenture), and (iv) shall be deemed to have (a) consented to the exercise of any U.K. Bail-In Power as it may be imposed without any
prior notice by the Relevant U.K. Resolution Authority of its decision to exercise such power with respect to the Securities and (b) authorized, directed and requested DTC and any direct participant in DTC or other intermediary through which it
holds such Securities to take any and all necessary action, if required, to implement the exercise of any U.K. Bail-In Power with respect to the Securities as it may be imposed, without any further action or direction on the part of such Holder and
such beneficial owner or the Trustee. 
 Each Holder and Beneficial Owner that acquires its Securities in the secondary market shall be
deemed to acknowledge and agree to be bound by and consent to the same provisions specified in the Indenture to the same extent as the Holders and Beneficial Owners of the Securities that acquire the Securities upon their initial issuance,
including, without limitation, with respect to the acknowledgement and agreement to be bound by and consent to the terms of the Securities, including in relation to the U.K. Bail-In Power. 

Upon the exercise of the U.K. Bail-In Power by the Relevant U.K. Resolution Authority with respect to the Securities, the Company shall
provide a written notice to DTC as soon as practicable regarding such exercise of the U.K. Bail-In Power for purposes of notifying Holders and beneficial owners of such occurrence. The Company shall also deliver a copy of such notice to the Trustee
for information purposes. 
 The Company’s obligations to indemnify the Trustee in accordance with Section 6.07 of the Indenture
shall survive any exercise of the U.K. Bail-In Power by the Relevant U.K. Resolution Authority with respect to the Securities. 
 The
exercise of the U.K. Bail-In Power by the Relevant U.K. Resolution Authority with respect to the Securities shall not constitute an Event of Default under the Indenture. 

The Securities shall constitute the Company’s direct, unconditional, unsecured and unsubordinated obligations and shall at all times rank
pari passu among themselves. In the event of a winding-up or administration of the Company, the Securities shall rank pari passu with all other outstanding unsecured and unsubordinated obligations of the Company, present and future,
except such obligations as are preferred by operation of law. 
 The Indenture permits, with certain exceptions as therein provided, the
amendment thereof and the modification of the rights and obligations of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the
Holders of not less than a majority in aggregate in principal amount of the Securities then Outstanding of each series to be affected. The Indenture also contains provisions 

 
permitting the Holders of a majority in aggregate principal amount of the Securities of each series then Outstanding, on behalf of the Holders of all Securities of such series, to waive
compliance by the Company with certain provisions of the Indenture and certain past Event of Defaults under the Indenture and their consequences. Any such consent or waiver by the Holder of this Security shall be conclusive and binding upon such
Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Security. 

As provided in and subject to the provisions of the Indenture, the Holder of this Security shall not have any right to institute any
proceeding, judicial or otherwise, with respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy thereunder, unless such Holder shall have previously given the Trustee written notice of a continuing Event of
Default with respect to the Securities of this series, the Holders of not less than 25% in aggregate principal amount of the Securities of this series then Outstanding shall have made written request to the Trustee to institute proceedings in
respect of such Event of Default as Trustee and offered to the Trustee security or indemnity satisfactory to the Trustee in its sole discretion against the costs, expenses and liabilities to be incurred in compliance with such request, the Trustee
shall not have received from the Holders of a majority in principal amount of Securities of this series then Outstanding a direction inconsistent with such request, and shall have failed to institute any such proceeding, for sixty (60) days
after receipt of such notice, request and offer of indemnity. 
 Notwithstanding any contrary provisions in this Security, nothing shall
impair the right of a Holder of this Security under the Trust Indenture Act, absent such Holder’s consent, to sue for any payments due but unpaid with respect to this Security. 

As provided in the Indenture and subject to certain limitations therein set forth, the transfer of this Security is registrable in the Senior
Debt Security Register, upon surrender of this Security for registration of transfer at the office or agency of the Company in any place where the principal of this Security is payable, duly endorsed by, or accompanied by a written instrument of
transfer in form satisfactory to the Company and the Senior Debt Security Registrar duly executed by, the Holder hereof or his attorney duly authorized in writing. Thereupon one or more new Securities of this series and of like tenor, of authorized
denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees. 
 This Security, and
any other Securities of this series and of like tenor, are issuable only in registered form without coupons in initial denominations of $200,000 and increments of $1,000 thereafter. The denominations cannot be changed without the consent of the
Trustee. 

 No service charge shall be made for any such registration of transfer or exchange, but the
Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. 
 Prior to
due presentment of this Security for registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not
this Security be overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the contrary. 
 This
Security shall be governed by and construed in accordance with the laws of the State of New York.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]